Natural Product: NPC181786
Natural Product ID:   | NPC181786 |
Common Name*:   | Phenylmethylsulfonylfluoride |
IUPAC Name:   | phenylmethanesulfonyl fluoride |
Synonyms:   | Phenylmethylsulfonyl Fluoride |
Standard InCHIKey:   | YBYRMVIVWMBXKQ-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C7H7FO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2 |
SMILES:   | c1ccc(cc1)CS(=O)(=O)F
|
Synthetic Gene Cluster:   |
n.a. |
ChEMBL Identifier:   |
CHEMBL190503 |
PubChem CID:   |
4784 |
Chemical Classification**:   |
-
CHEMONTID:0000000 [Organic compounds]
-
[CHEMONTID:0002448] Benzenoids
-
[CHEMONTID:0002279] Benzene and substituted derivatives
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
  Species Source
Organism ID |
Organism Name |
Taxonomy Level |
Family |
SuperKingdom |
Isolation Part |
Collection Location |
Collection Time |
Reference |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
root |
n.a. |
PMID[11374966] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[16038550] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[17583950] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[18855446] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[20455578] |
NPO6876 |
Ixora coccinea |
Species |
Rubiaceae |
Eukaryota |
aerial parts |
collected on the campus of Kaohsiung Medical University, Taiwan |
2007-Oct |
PMID[21106454] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[21775156] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[23286284] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[24108414] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[27569393] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[29185738] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[30351923] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
root |
n.a. |
PMID[3655791] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
roots |
n.a. |
n.a. |
PMID[9834151] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[HerDing] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCMID] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCM_Taiwan] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TM-MC] |
NPO6876 |
Ixora coccinea |
Species |
Rubiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO5743 |
Salvia miltiorrhiza |
Species |
Lamiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  NP Quantity Composition/Concentration
Organism ID |
NP ID |
Organism Material Preparation |
Organism Part |
NP Quantity (Standard) |
NP Quantity (Minimum) |
NP Quantity (Maximum) |
Quantity Unit |
Reference |
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  Biological Activity
Activity Type |
# Activity |
GI50 |
56 |
IC50 |
21 |
Ki |
2 |
LD50 |
2 |
Others |
15 |
Potency |
2 |
Activity Type |
# Activity |
Cell Line |
58 |
Individual Protein |
11 |
NON-MOLECULAR |
14 |
Organism |
5 |
Others |
6 |
Protein Family |
3 |
SINGLE PROTEIN |
1 |
Target ID |
Target Type |
Target Name |
Target Organism |
Activity Type |
Activity Relation |
Value |
Unit |
Reference |
NPT1418 |
Individual Protein |
Anandamide amidohydrolase |
Homo sapiens |
IC50 |
= |
13000.0 |
nM |
PMID[475532] |
NPT189 |
Cell Line |
Vero |
Chlorocebus aethiops |
LD50 |
= |
132.77 |
uM |
PMID[475544] |
NPT2740 |
Cell Line |
Neutrophils |
|
IC50 |
= |
109518.5 |
nM |
PMID[475545] |
NPT279 |
Individual Protein |
Leukocyte elastase |
Homo sapiens |
IC50 |
= |
95219.3 |
nM |
PMID[475545] |
NPT279 |
Individual Protein |
Leukocyte elastase |
Homo sapiens |
IC50 |
= |
52161.7 |
nM |
PMID[475545] |
NPT368 |
Cell Line |
SN12C |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT367 |
Cell Line |
MDA-N |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT370 |
Cell Line |
NCI-H23 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT371 |
Cell Line |
UO-31 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT369 |
Cell Line |
ACHN |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT372 |
Cell Line |
HOP-92 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT374 |
Cell Line |
SF-539 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT90 |
Cell Line |
DU-145 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT373 |
Cell Line |
SK-MEL-5 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT375 |
Cell Line |
Malme-3M |
Homo sapiens |
GI50 |
n.a. |
486.41 |
nM |
PMID[475550] |
NPT111 |
Cell Line |
K562 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT377 |
Cell Line |
OVCAR-3 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT376 |
Cell Line |
A498 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT379 |
Cell Line |
HOP-62 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT112 |
Cell Line |
MOLT-4 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT378 |
Cell Line |
NCI/ADR-RES |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT380 |
Cell Line |
U-251 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT381 |
Cell Line |
OVCAR-8 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT382 |
Cell Line |
OVCAR-5 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT383 |
Cell Line |
SNB-19 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT385 |
Cell Line |
SR |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT82 |
Cell Line |
MDA-MB-231 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT323 |
Cell Line |
SW-620 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT384 |
Cell Line |
TK-10 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT455 |
Cell Line |
NCI-H522 |
Homo sapiens |
GI50 |
n.a. |
39084.09 |
nM |
PMID[475550] |
NPT387 |
Cell Line |
M14 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT386 |
Cell Line |
KM12 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT389 |
Cell Line |
RPMI-8226 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT388 |
Cell Line |
NCI-H322M |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT456 |
Cell Line |
OVCAR-4 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT457 |
Cell Line |
BT-549 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT390 |
Cell Line |
LOX IMVI |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT147 |
Cell Line |
SK-MEL-2 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT81 |
Cell Line |
A549 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT391 |
Cell Line |
HCC 2998 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT392 |
Cell Line |
SNB-75 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT148 |
Cell Line |
HCT-15 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT395 |
Cell Line |
SF-268 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT393 |
Cell Line |
HCT-116 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT83 |
Cell Line |
MCF7 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT394 |
Cell Line |
EKVX |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT306 |
Cell Line |
PC-3 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT146 |
Cell Line |
SK-OV-3 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT397 |
Cell Line |
NCI-H460 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT398 |
Cell Line |
UACC-62 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT400 |
Cell Line |
MDA-MB-435 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT308 |
Cell Line |
CAKI-1 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT399 |
Cell Line |
SF-295 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT458 |
Cell Line |
IGROV-1 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT401 |
Cell Line |
786-0 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT403 |
Cell Line |
UACC-257 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT404 |
Cell Line |
CCRF-CEM |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT405 |
Cell Line |
NCI-H226 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT170 |
Cell Line |
SK-MEL-28 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT139 |
Cell Line |
HT-29 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT407 |
Cell Line |
COLO 205 |
Homo sapiens |
GI50 |
n.a. |
100000.0 |
nM |
PMID[475550] |
NPT2982 |
Individual Protein |
Sn1-specific diacylglycerol lipase alpha |
Homo sapiens |
Inhibition |
= |
8.0 |
% |
PMID[475553] |
NPT3000 |
Individual Protein |
Monoglyceride lipase |
Homo sapiens |
Inhibition |
= |
5.0 |
% |
PMID[475553] |
NPT1260 |
Individual Protein |
Anandamide amidohydrolase |
Rattus norvegicus |
IC50 |
= |
833.0 |
nM |
PMID[475553] |
NPT1260 |
Individual Protein |
Anandamide amidohydrolase |
Rattus norvegicus |
Inhibition |
= |
100.0 |
% |
PMID[475553] |
NPT2982 |
Individual Protein |
Sn1-specific diacylglycerol lipase alpha |
Homo sapiens |
Inhibition |
= |
19.0 |
% |
PMID[475553] |
NPT6588 |
Individual Protein |
Leukocyte proteinase 3 |
Homo sapiens |
Inhibition |
= |
20.0 |
% |
PMID[475557] |
NPT279 |
Individual Protein |
Leukocyte elastase |
Homo sapiens |
Inhibition |
= |
20.0 |
% |
PMID[475557] |
NPT6588 |
Individual Protein |
Leukocyte proteinase 3 |
Homo sapiens |
IC50 |
= |
19230.0 |
nM |
PMID[475557] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
130930.0 |
nM |
PMID[475533] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
35680.0 |
nM |
PMID[475534] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
204080.0 |
nM |
PMID[475535] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
202300.0 |
nM |
PMID[475537] |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
T1/2 |
= |
52.0 |
hr |
PMID[475538] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
130900.0 |
nM |
PMID[475539] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
203500.0 |
nM |
PMID[475540] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
35.24 |
ug.mL-1 |
PMID[475541] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
95000.0 |
nM |
PMID[475542] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
130900.0 |
nM |
PMID[475543] |
NPT2255 |
Organism |
Toxoplasma gondii RH |
Toxoplasma gondii RH |
LD50 |
= |
27.98 |
uM |
PMID[475544] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
19.89 |
ug.mL-1 |
PMID[475546] |
NPT2 |
Others |
Unspecified |
|
Ki |
= |
13000.0 |
nM |
PMID[475547] |
NPT2 |
Others |
Unspecified |
|
Kinact |
= |
0.32 |
/min |
PMID[475547] |
NPT2 |
Others |
Unspecified |
|
IC50 |
= |
95000.0 |
nM |
PMID[475548] |
NPT2 |
Others |
Unspecified |
|
IC50 |
= |
95000.0 |
nM |
PMID[475549] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
131.0 |
ug.mL-1 |
PMID[475551] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
IC50 |
= |
22.8 |
ug.mL-1 |
PMID[475552] |
NPT2 |
Others |
Unspecified |
|
Inhibition |
= |
17.0 |
% |
PMID[475553] |
NPT2 |
Others |
Unspecified |
|
Inhibition |
< |
0.0 |
% |
PMID[475553] |
NPT1644 |
Protein Family |
Trypsin |
Homo sapiens |
IC50 |
= |
110000.0 |
nM |
PMID[475554] |
NPT1644 |
Protein Family |
Trypsin |
Homo sapiens |
Inhibition |
= |
87.4 |
% |
PMID[475554] |
NPT1644 |
Protein Family |
Trypsin |
Homo sapiens |
Ki |
= |
10010.0 |
nM |
PMID[475555] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
Potency |
n.a. |
749.3 |
nM |
PMID[475556] |
NPT20529 |
NON-MOLECULAR |
NON-PROTEIN TARGET |
n.a. |
Potency |
n.a. |
14950.2 |
nM |
PMID[475556] |
NPT20555 |
ORGANISM |
SARS-CoV-2 |
Severe acute respiratory syndrome coronavirus 2 |
Inhibition |
= |
15.9 |
% |
PMID[475559] |
NPT20556 |
SINGLE PROTEIN |
Replicase polyprotein 1ab |
Severe acute respiratory syndrome coronavirus 2 |
Inhibition |
= |
1.147 |
% |
PMID[475560] |
NPT20555 |
ORGANISM |
SARS-CoV-2 |
Severe acute respiratory syndrome coronavirus 2 |
Inhibition |
= |
0.1 |
% |
PMID[475561] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
  Chemically structural similarity: I. Similar Active Natural Products in NPASS
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC181786 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1504 |
0.1-0.2 | 8144 |
0.2-0.3 | 16897 |
0.3-0.4 | 13255 |
0.4-0.5 | 2246 |
0.5-0.6 | 501 |
0.6-0.7 | 112 |
0.7-0.8 | 34 |
0.8-0.85 | 2 |
0.85-0.9 | 1 |
0.9-0.95 | 0 |
0.95-1 | 1 |
  Chemically structural similarity: II. Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC181786 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 826 |
0.1-0.2 | 1000 |
0.2-0.3 | 3380 |
0.3-0.4 | 2780 |
0.4-0.5 | 893 |
0.5-0.6 | 234 |
0.6-0.7 | 33 |
0.7-0.8 | 4 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7284 |
Intermediate Similarity |
NPD423 |
Phase 3 |
0.7093 |
Intermediate Similarity |
NPD2811 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD1628 |
Approved |
0.6977 |
Remote Similarity |
NPD1629 |
Approved |
0.6944 |
Remote Similarity |
NPD675 |
Discontinued |
0.6933 |
Remote Similarity |
NPD9497 |
Clinical (unspecified phase) |
0.686 |
Remote Similarity |
NPD9186 |
Approved |
0.686 |
Remote Similarity |
NPD9184 |
Approved |
0.6849 |
Remote Similarity |
NPD173 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD1007 |
Discontinued |
0.6703 |
Remote Similarity |
NPD3832 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD9728 |
Phase 1 |
0.6628 |
Remote Similarity |
NPD1697 |
Approved |
0.65 |
Remote Similarity |
NPD9716 |
Approved |
0.6489 |
Remote Similarity |
NPD4737 |
Phase 2 |
0.6484 |
Remote Similarity |
NPD837 |
Approved |
0.6421 |
Remote Similarity |
NPD6354 |
Discontinued |
0.6375 |
Remote Similarity |
NPD505 |
Clinical (unspecified phase) |
0.6344 |
Remote Similarity |
NPD3093 |
Approved |
0.6344 |
Remote Similarity |
NPD838 |
Approved |
0.6329 |
Remote Similarity |
NPD292 |
Approved |
0.6329 |
Remote Similarity |
NPD294 |
Approved |
0.6316 |
Remote Similarity |
NPD1796 |
Phase 3 |
0.6304 |
Remote Similarity |
NPD1409 |
Phase 3 |
0.6289 |
Remote Similarity |
NPD1387 |
Phase 1 |
0.6265 |
Remote Similarity |
NPD225 |
Approved |
0.6265 |
Remote Similarity |
NPD227 |
Approved |
0.625 |
Remote Similarity |
NPD1795 |
Discontinued |
0.6235 |
Remote Similarity |
NPD9250 |
Approved |
0.619 |
Remote Similarity |
NPD9490 |
Approved |
0.6186 |
Remote Similarity |
NPD1386 |
Phase 1 |
0.6176 |
Remote Similarity |
NPD9072 |
Clinical (unspecified phase) |
0.6173 |
Remote Similarity |
NPD80 |
Approved |
0.6173 |
Remote Similarity |
NPD9588 |
Approved |
0.6173 |
Remote Similarity |
NPD9589 |
Approved |
0.6173 |
Remote Similarity |
NPD9594 |
Approved |
0.6173 |
Remote Similarity |
NPD9591 |
Approved |
0.6173 |
Remote Similarity |
NPD9593 |
Approved |
0.6173 |
Remote Similarity |
NPD9592 |
Approved |
0.6173 |
Remote Similarity |
NPD9590 |
Approved |
0.6145 |
Remote Similarity |
NPD9294 |
Approved |
0.6082 |
Remote Similarity |
NPD9248 |
Phase 1 |
0.6076 |
Remote Similarity |
NPD1673 |
Approved |
0.6047 |
Remote Similarity |
NPD226 |
Approved |
0.602 |
Remote Similarity |
NPD4321 |
Approved |
0.6 |
Remote Similarity |
NPD5206 |
Clinical (unspecified phase) |
0.5978 |
Remote Similarity |
NPD4728 |
Approved |
0.596 |
Remote Similarity |
NPD557 |
Discovery |
0.5952 |
Remote Similarity |
NPD4144 |
Approved |
0.5952 |
Remote Similarity |
NPD603 |
Approved |
0.5952 |
Remote Similarity |
NPD4147 |
Approved |
0.593 |
Remote Similarity |
NPD1617 |
Discontinued |
0.593 |
Remote Similarity |
NPD1507 |
Clinical (unspecified phase) |
0.5922 |
Remote Similarity |
NPD2298 |
Clinical (unspecified phase) |
0.5909 |
Remote Similarity |
NPD9491 |
Approved |
0.5909 |
Remote Similarity |
NPD3971 |
Phase 1 |
0.5882 |
Remote Similarity |
NPD9397 |
Approved |
0.5882 |
Remote Similarity |
NPD296 |
Approved |
0.5882 |
Remote Similarity |
NPD79 |
Approved |
0.5882 |
Remote Similarity |
NPD9393 |
Approved |
0.5882 |
Remote Similarity |
NPD9563 |
Approved |
0.5882 |
Remote Similarity |
NPD295 |
Approved |
0.5882 |
Remote Similarity |
NPD9564 |
Approved |
0.5882 |
Remote Similarity |
NPD293 |
Approved |
0.5862 |
Remote Similarity |
NPD942 |
Approved |
0.5842 |
Remote Similarity |
NPD1406 |
Approved |
0.5816 |
Remote Similarity |
NPD1067 |
Discontinued |
0.5814 |
Remote Similarity |
NPD508 |
Approved |
0.5814 |
Remote Similarity |
NPD590 |
Approved |
0.5814 |
Remote Similarity |
NPD589 |
Approved |
0.5814 |
Remote Similarity |
NPD507 |
Approved |
0.5814 |
Remote Similarity |
NPD1053 |
Approved |
0.5814 |
Remote Similarity |
NPD1051 |
Approved |
0.5814 |
Remote Similarity |
NPD1052 |
Approved |
0.5814 |
Remote Similarity |
NPD1475 |
Approved |
0.5778 |
Remote Similarity |
NPD5734 |
Clinical (unspecified phase) |
0.5758 |
Remote Similarity |
NPD3135 |
Clinical (unspecified phase) |
0.5747 |
Remote Similarity |
NPD3903 |
Approved |
0.5747 |
Remote Similarity |
NPD914 |
Suspended |
0.5747 |
Remote Similarity |
NPD3979 |
Approved |
0.5747 |
Remote Similarity |
NPD260 |
Discontinued |
0.5747 |
Remote Similarity |
NPD5372 |
Approved |
0.5747 |
Remote Similarity |
NPD5371 |
Approved |
0.5747 |
Remote Similarity |
NPD3904 |
Approved |
0.5747 |
Remote Similarity |
NPD3981 |
Approved |
0.573 |
Remote Similarity |
NPD1800 |
Clinical (unspecified phase) |
0.573 |
Remote Similarity |
NPD2001 |
Discontinued |
0.5729 |
Remote Similarity |
NPD9260 |
Approved |
0.5714 |
Remote Similarity |
NPD9257 |
Approved |
0.5714 |
Remote Similarity |
NPD9259 |
Approved |
0.5701 |
Remote Similarity |
NPD7077 |
Approved |
0.5701 |
Remote Similarity |
NPD7076 |
Approved |
0.5682 |
Remote Similarity |
NPD4027 |
Approved |
0.5682 |
Remote Similarity |
NPD472 |
Approved |
0.5682 |
Remote Similarity |
NPD4026 |
Approved |
0.5682 |
Remote Similarity |
NPD3035 |
Approved |
0.567 |
Remote Similarity |
NPD3458 |
Approved |
0.567 |
Remote Similarity |
NPD3457 |
Approved |
0.567 |
Remote Similarity |
NPD3456 |
Approved |
0.5652 |
Remote Similarity |
NPD4793 |
Discontinued |
0.5652 |
Remote Similarity |
NPD650 |
Approved |
0.5652 |
Remote Similarity |
NPD1087 |
Approved |
0.5652 |
Remote Similarity |
NPD9538 |
Approved |
0.5652 |
Remote Similarity |
NPD506 |
Clinical (unspecified phase) |
0.5652 |
Remote Similarity |
NPD1282 |
Approved |
0.5644 |
Remote Similarity |
NPD744 |
Clinical (unspecified phase) |
0.5618 |
Remote Similarity |
NPD4170 |
Approved |
0.5618 |
Remote Similarity |
NPD4701 |
Clinical (unspecified phase) |
0.5618 |
Remote Similarity |
NPD4169 |
Approved |
0.5604
|
Remote Similarity |
NPD111 |
Approved |